These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 7852106)

  • 1. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
    Murray KJ; Nelson DF; Scott C; Fischbach AJ; Porter A; Farnan N; Curran WJ
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):453-9. PubMed ID: 7852106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
    Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ
    Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group.
    Nelson DF; Diener-West M; Horton J; Chang CH; Schoenfeld D; Nelson JS
    NCI Monogr; 1988; (6):279-84. PubMed ID: 3281031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02.
    Curran WJ; Scott CB; Nelson JS; Weinstein AS; Phillips TL; Murray K; Fischbach AJ; Yakar D; Schwade JG; Powlis WD
    Cancer; 1992 Dec; 70(12):2909-17. PubMed ID: 1451073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality-adjusted survival after tumor resection and/or radiation therapy for elderly patients with glioblastoma multiforme.
    Muacevic A; Kreth FW
    J Neurol; 2003 May; 250(5):561-8. PubMed ID: 12736735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02.
    Curran WJ; Scott CB; Weinstein AS; Martin LA; Nelson JS; Phillips TL; Murray K; Fischbach AJ; Yakar D; Schwade JG
    J Clin Oncol; 1993 May; 11(5):857-62. PubMed ID: 8487050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.
    Selker RG; Shapiro WR; Burger P; Blackwood MS; Arena VC; Gilder JC; Malkin MG; Mealey JJ; Neal JH; Olson J; Robertson JT; Barnett GH; Bloomfield S; Albright R; Hochberg FH; Hiesiger E; Green S;
    Neurosurgery; 2002 Aug; 51(2):343-55; discussion 355-7. PubMed ID: 12182772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
    Ali AN; Zhang P; Yung WKA; Chen Y; Movsas B; Urtasun RC; Jones CU; Choi KN; Michalski JM; Fischbach AJ; Markoe AM; Schultz CJ; Penas-Prado M; Garg MK; Hartford AC; Kim HE; Won M; Curran WJ
    J Neurooncol; 2018 Mar; 137(1):39-47. PubMed ID: 29404979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
    Nelson DF; Curran WJ; Scott C; Nelson JS; Weinstein AS; Ahmad K; Constine LS; Murray K; Powlis WD; Mohiuddin M
    Int J Radiat Oncol Biol Phys; 1993 Jan; 25(2):193-207. PubMed ID: 8380567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
    Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of short-course accelerated whole brain radiation therapy for multiple brain metastases.
    Caravatta L; Deodato F; Ferro M; Macchia G; Massaccesi M; Cilla S; Padula GD; Mignogna S; Tambaro R; Carrozza F; Flocco M; Cantore G; Scapati A; Buwenge M; Sticca G; Valentini V; Cellini N; Morganti AG
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e463-8. PubMed ID: 22909415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.
    Murray KJ; Scott C; Greenberg HM; Emami B; Seider M; Vora NL; Olson C; Whitton A; Movsas B; Curran W
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):571-4. PubMed ID: 9336134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
    Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02).
    Corn BW; Yousem DM; Scott CB; Rotman M; Asbell SO; Nelson DF; Martin L; Curran WJ
    Cancer; 1994 Nov; 74(10):2828-35. PubMed ID: 7954244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma.
    Tsao MN; Mehta MP; Whelan TJ; Morris DE; Hayman JA; Flickinger JC; Mills M; Rogers CL; Souhami L
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):47-55. PubMed ID: 16111571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
    Buckner JC; Ballman KV; Michalak JC; Burton GV; Cascino TL; Schomberg PJ; Hawkins RB; Scheithauer BW; Sandler HM; Marks RS; O'Fallon JR; ;
    J Clin Oncol; 2006 Aug; 24(24):3871-9. PubMed ID: 16921039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
    Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
    J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13.
    Fu KK; Pajak TF; Marcial VA; Ortiz HG; Rotman M; Asbell SO; Coia LR; Vora NL; Byhardt R; Rubin P
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):577-88. PubMed ID: 7790242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.